Single-dose daclizumab induction therapy in patients with liver transplantation

World Journal of Gastroenterology

Volumn 9, Issue 8, 2003, Pages 1881-1883

  Yan, Lu Nan ^a   Wang, Wei ^a   Li, Bo ^a   Lu, Shi Chun ^a   Wen, Tian Fu ^a   Lin, Qi Yuan ^a   Zeng, Yong ^a   Cheng, Nan Sheng ^a   Zhao, Ji Chun ^a   Dai, Yue Meng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BILIRUBIN; CEFALEXIN; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PREDNISONE; STEROID; TACROLIMUS; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BILE LEAKAGE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; FEMALE; GRAFT INFECTION; GRAFT SURVIVAL; HEART FAILURE; HEMOPERITONEUM; HUMAN; INCIDENCE; INTESTINE INFECTION; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MOUTH ULCER; MYCOSIS; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STRESS ULCER; ULCER PERFORATION; VIRUS INFECTION;

EID: 0042427761     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i8.1881     Document Type: Article

References (32)

1. Eckhoff DE, Mcguire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867-1872
2. Kwekkeboom J, Zondervan PE, Kuijpers MA, Tilanus HW, Metselaar HJ. Fine-needle aspiration cytology in the diagnosis of acute rejection after liver transplantation. Br J Surg 2003; 90: 246-247
3. Ramji A, Yoshida EM, Bain VG, Kneteman NM, Scudamore CH, Ma MM, Steinbrecher UP, Gutfreund KS, Erb SR, Partovi N, Chung SW, Shapiro J, Wong WW. Late acute rejection after liver transplantation: The Western Canada experience. Liver Transpl 2002; 8: 945-951
4. Levy GA. Neoral is superior to FK506 in liver transplantation. Transplant Proc 1998; 30: 1812-1815
5. Niemeyer G, Koch M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454-460
6. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: A review of its use in the management of organ transplantation. Biodrugs 2001; 15: 745-773
7. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002; 73: 1640-1646
8. Yan LN, Li B, Lu SC, Jin LR, Wen TF, Wu XD, Jia QB, Zhou Y, Wu YT. Orthotopic liver transplantation: A report of 15 cases. Zhonghua Qiguan Yizhi Zazhi 2001; 21: 275-277
9. Ankersmit HJ, Roth G, Zuckermann A, Moser B, Obermaier R, Taghavi S, Brunner M, Wieselthaler G, Lanzenberger M, Ullrich R, Laufer G, Grimm M, Wolner E. Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection. Am J Transplant 2003; 3: 231-234
10. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282-285
11. Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 123-131
12. Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, Flavin K, Lowell JA, Shenoy S, Howard TK, Ramachandran V, Irish W, Schnitzle MA, Brennan DC. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473-475
13. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, Mcmaster P, Dunn DC, Graddock GN, Henderson RG, Aziz S, Lewis P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet, 1979; 2: 1033-1036
14. Lerut JP, Ciccarelli O, Mauel E, Gheerardhyn R, Talpe S, Sempoux C, Laterre PF, Roggen FM, Van Leeuw V, Otte JB, Gianello P. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study. Transpl Int 2001; 14: 420-428
15. Venkiteswaran K, Sgoutas DS, Santanam N, Neylan JF. Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients. Transpl Int 2001; 14: 405-410
16. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Sirolimus Renal Function Study Group Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567
17. Meier-Kriesche HU, Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant 2002; 2: 100-104
18. Fung JJ, Todo S, Tzakis A, Demetris A, Jain A, Abu-Elmaged K, Alessiani M, Starzl TE. Conversion of liver allograft recipients from Cyclosporine to FK506-based immunosuppression: Benefits and pitfalls. Transplant Proc 1991; 23 (1Pt 1): 14-21
19. Kato T, Sato Y, Kurasaki I, Yamamoto S, Hirano K, Nakatsuka H, Kobayashi T, Kameyama H, Watanabe T, Hatakeyama K. FK506 may suppress liver injury during the early period following living-related liver transplantation. Transplant Proc 2003; 35: 79
20. Chen JW, Pehlivan M, Gunson BK, Buckels JA, McMaster P, Mayer D. Ten-year results of a randomised prospective study of FK506 versus Cyclosporine in management of primary orthotopic liver transplantation. Transplant Proc 2002; 34: 1507-1510
21. Ahmad SM, Stegman Z, Fructhman S, Asbell PA. Successful treatment of acute ocular graft-versus-host disease with tacrolimus (FK506). Cornea 2002; 21: 432-433
22. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and Cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782
23. Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O, Hurault De Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56
24. Boggi U, Vistoli F, Coppelli A, Marchetti P, Rizzo G, Mosca F. Use of basiliximab in conjunction with either Neora/MMF/steroids of Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. Transplant Proc 2001; 33: 3201-3202
25. Ciancio G, Burke GW, Miller J. Current treatment practice in immunosuppression. Expert Opin Pharmacother 2000; 1: 1307-1330
26. Mouly-Bandini A. A new immunosuppressor: CellCept. Presse Med 2001; 30: 66-67
27. Wu MJ, Shu KH, Cheng CH, Chen CH, Lian JD. MMF-based regimen in maintenance therapy after kidney transplantation. Transplant Proc 2000; 32: 1748-1750
28. Van Assche G, Dalle I, Norman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98: 369-376
29. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, Sherr A, Gottlieb AB. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-458
30. Light JA, Sasaki TM, Ghasemian R, Barhyte DY, Fowlkes DL. Daclizumab induction/tacrolimus sparing: A randomized prospective trial in renal transplantation. Clin Transplant 2002; 16 (Suppl 7): 30-33
31. Ciancio G, Burke GW, Suzart K, Mattiazzi A, Rosen A, Zilleruello G, Abitbol C, Montane B, Miller J. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant Proc 2002; 34: 1944-1945
32. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165